Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD 0.0620
+0.0025 (4.20%)
Jul 31, 2026, 4:10 PM AEST
Neurizon Therapeutics Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Income | -14.85 | -16.59 | -7.67 | -6.21 | -1.71 | -1.34 |
Depreciation & Amortization | 0 | 0 | 0 | 0.33 | 0.31 | 0.3 |
Loss (Gain) From Sale of Assets | - | - | -1.23 | 0 | - | - |
Asset Writedown & Restructuring Costs | - | - | 3.11 | 3.58 | 0.03 | - |
Stock-Based Compensation | 0.52 | 0.52 | 0.37 | -0.01 | -0.05 | 0.16 |
Other Operating Activities | -4.9 | - | - | 0.51 | - | 0.05 |
Change in Accounts Receivable | 0.02 | 0.02 | 0.14 | -0.04 | 0.06 | 0.06 |
Change in Inventory | - | - | - | -0 | -0.03 | -0.15 |
Change in Accounts Payable | 0.48 | 0.48 | 0.53 | 0.32 | 0.04 | 0 |
Change in Other Net Operating Assets | 1.28 | 1.28 | -0.41 | -0.04 | 0.01 | -0.01 |
Operating Cash Flow | -17.45 | -14.29 | -5.17 | -1.56 | -1.33 | -0.94 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Capital Expenditures | -0.01 | -0 | - | -0.03 | -0.04 | -0.1 |
Divestitures | - | - | -0.17 | - | - | - |
Sale (Purchase) of Intangibles | - | - | - | -0 | - | -0.04 |
Investment in Securities | 3 | -0.02 | -1 | - | - | - |
Investing Cash Flow | 2.99 | -0.02 | -1.17 | -0.03 | -0.04 | -0.14 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Long-Term Debt Issued | - | - | - | - | 0.21 | - |
Long-Term Debt Repaid | - | - | - | -0.35 | -0.16 | -0.32 |
Net Debt Issued (Repaid) | 1.49 | - | - | -0.35 | 0.05 | -0.32 |
Issuance of Common Stock | 11.53 | 8.8 | 12.91 | 2.24 | - | 1.58 |
Other Financing Activities | -0.75 | -0.04 | 0.43 | - | 0.72 | -0.04 |
Financing Cash Flow | 12.27 | 8.76 | 13.34 | 1.89 | 0.77 | 1.22 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Cash Flow | -2.19 | -5.55 | 7.01 | 0.29 | -0.6 | 0.14 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Free Cash Flow | -17.46 | -14.29 | -5.17 | -1.6 | -1.38 | -1.04 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -291.97% | -929.50% | -614.05% | -183.02% | -30.50% | -28.43% |
Free Cash Flow Per Share | -0.04 | -0.03 | -0.01 | -0.01 | -0.00 | -0.00 |
Levered Free Cash Flow | -8.85 | -9.21 | -3.65 | 0.63 | -0.77 | -0.62 |
Unlevered Free Cash Flow | -8.77 | -9.21 | -3.65 | 0.63 | -0.71 | -0.57 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash Interest Paid | - | - | - | 0.08 | 0.09 | 0.03 |
Change in Working Capital | 1.78 | 1.78 | 0.25 | 0.24 | 0.07 | -0.1 |